Aneurysmal Subarachnoid Hemorrhage Multi-Omics Research Program

NCT07270419 | Recruiting

• 2 other identifiers: KY2025-175-012024ZD0539700
• Study Type: observational
• Target: 2,000
• Locations: 1 country
• Sites: 1

Brief Summary

Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening cerebrovascular emergency with high mortality and disability rates. Despite advances in neuroimaging and interventional techniques, outcomes remain poor for many patients due to complex post-rupture complications such as delayed cerebral ischemia (DCI), pneumonia, and other systemic injuries. These secondary events critically affect neurological recovery, yet their molecular mechanisms are not fully understood. This multicenter study aims to investigate the biological basis of post-rupture complications and prognosis in patients with aSAH through integrated multi-omics and clinical data analysis. Biospecimens including blood, cerebrospinal fluid, urine, and other relevant tissues will be collected for genomic, transcriptomic, proteomic, metabolomic, and imaging-omic profiling. By linking molecular data with clinical and imaging indicators, the study seeks to identify key pathways and biomarkers associated with secondary injury and outcome heterogeneity.

Conditions

Aneurysmal Subarachnoid Hemorrhage

Keywords

Multi-Omics; Prognosis; Complications; Aneurysmal Subarachnoid Hemorrhage

Outcome Measures

Primary Outcomes (1)

• Modified Rankin Scale (mRS) score for functional outcome

  Functional outcome will be evaluated using the modified Rankin Scale (mRS), ranging from 0 (no symptoms) to 6 (death). Higher scores indicate greater disability. The distribution of mRS scores will be analyzed at predefined follow-up time points.

  3, 6, and 12 months after onset

Secondary Outcomes (5)

• Incidence of rebleeding

  After onset, up to 30 days

• Incidence of delayed cerebral ischemia (DCI)

  After onset, up to 30 days

• Incidence of anemia

  After onset, up to 30 days

• Incidence of pneumonia

  From enrollment to the end of follow-up at 3 months

• Incidence of deep vein thrombosis (DVT)

  After onset, up to 30 days

Eligibility Criteria

• Age: 18 Years+
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Adult patients (≥18 years) with aneurysmal subarachnoid hemorrhage (aSAH) confirmed by CTA, or DSA, whose aneurysms are treated by microsurgical clipping or endovascular coiling within 72 hours after onset. Participants will be consecutively recruited from multiple tertiary neurosurgical centers.

You may qualify if:

• Adult patients aged ≥18 years;
• Confirmed diagnosis of aneurysmal subarachnoid hemorrhage (aSAH) by CTA, or DSA;
• Aneurysm secured by either microsurgical clipping or endovascular coiling during hospitalization;
• Time from onset to aneurysm treatment ≤ 72 hours;
• Availability of biospecimens, including blood, cerebrospinal fluid (CSF), urine, or fecal samples collected during hospitalization;
• Signed informed consent obtained from the patient or legal representative.

You may not qualify if:

• History of previous intracranial aneurysm surgery or embolization;
• Non-aneurysmal SAH, traumatic SAH, or perimesencephalic non-aneurysmal hemorrhage;
• Presence of malignancy, severe hepatic or renal dysfunction, or other systemic diseases that may affect survival or biomarker expression;
• Severe cardiorespiratory insufficiency or unstable medical condition precluding study participation;
• Pregnancy or lactation;
• Refusal to participate or withdrawal of consent.

Sponsors & Collaborators

• Xiaolin Chen, MD: lead
• Peking Union Medical College: collaborator

Study Sites (1)

Beijing Tiantan Hospital

Beijing, Beijing Municipality, 100070, China

RECRUITING

MeSH Terms

Conditions

Subarachnoid Hemorrhage

Condition Hierarchy (Ancestors)

Intracranial Hemorrhages; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Hemorrhage; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Runting Li, MD

CONTACT

+86 15753166690; tt18080lrt@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 12 Months
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Prof.

Study Record Dates

• First Submitted: November 26, 2025
• First Posted: December 8, 2025
• Study Start: November 1, 2023
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2027
• Last Updated: December 8, 2025

Record last verified: 2025-11

Locations

CN (1)